Patents by Inventor Olof Mikael Trollsas
Olof Mikael Trollsas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11974979Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.Type: GrantFiled: April 22, 2022Date of Patent: May 7, 2024Assignee: RESURGE THERAPEUTICS, INC.Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
-
Patent number: 11957654Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.Type: GrantFiled: December 6, 2022Date of Patent: April 16, 2024Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
-
Publication number: 20240115544Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.Type: ApplicationFiled: December 4, 2023Publication date: April 11, 2024Inventors: Olof Mikael TROLLSAS, John J. STANKUS, Shahram Shawn GHOLAMI
-
Patent number: 11911499Abstract: A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.Type: GrantFiled: November 6, 2020Date of Patent: February 27, 2024Assignee: Resurge Therapeutics, Inc.Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
-
Publication number: 20230248688Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.Type: ApplicationFiled: December 6, 2022Publication date: August 10, 2023Inventors: Olof Mikael TROLLSAS, John J. STANKUS, Shahram Shawn GHOLAMI
-
Publication number: 20230240979Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.Type: ApplicationFiled: April 22, 2022Publication date: August 3, 2023Inventors: OLOF MIKAEL TROLLSAS, JOHN J STANKUS, SHAHRAM SHAWN GHOLAMI
-
Patent number: 11602516Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.Type: GrantFiled: April 22, 2022Date of Patent: March 14, 2023Assignee: RESURGE THERAPEUTICS INC.Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
-
Publication number: 20220031606Abstract: A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.Type: ApplicationFiled: November 6, 2020Publication date: February 3, 2022Inventors: Olof Mikael TROLLSAS, John J. STANKUS, Shahram Shawn GHOLAMI
-
Patent number: 9353218Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.Type: GrantFiled: June 14, 2013Date of Patent: May 31, 2016Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
-
Publication number: 20140017200Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.Type: ApplicationFiled: July 15, 2013Publication date: January 16, 2014Inventors: Eugene T. Michal, Olof Mikael Trollsas, Shubhayu Basu
-
Patent number: 8617584Abstract: The present invention relates generally to synthetic polymer compositions that form interpenetrating polymer networks. In a preferred embodiment, the compositions comprise two multifunctionally activated synthetic polymers, along with a tensile strength enhancer. Such compositions form matrices that exhibit superior cohesive strength and in many instances can serve as adequate replacements for surgical means of attaching tissues, such as sutures, sponges and medical staples.Type: GrantFiled: May 25, 2010Date of Patent: December 31, 2013Assignee: Angiodevice International GmbHInventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Publication number: 20130289235Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.Type: ApplicationFiled: June 14, 2013Publication date: October 31, 2013Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
-
Patent number: 8486387Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.Type: GrantFiled: April 7, 2010Date of Patent: July 16, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Eugene Michal, Olof Mikael Trollsas, Shubhayu Basu
-
Patent number: 8486386Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.Type: GrantFiled: April 7, 2010Date of Patent: July 16, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Eugene Michal, Olof Mikael Trollsas, Shubhayu Basu
-
Patent number: 8486437Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.Type: GrantFiled: September 14, 2012Date of Patent: July 16, 2013Assignee: Angiotech Pharmaceuticals (US), Inc.Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
-
Patent number: 8481073Abstract: Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.Type: GrantFiled: October 24, 2011Date of Patent: July 9, 2013Assignee: AngioDevice International GmbHInventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline A. Schroeder, David M. Gravett, Philip M. Toleikis
-
Patent number: 8460708Abstract: Kits comprising dry power compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The dry powder composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked biomaterials include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.Type: GrantFiled: October 24, 2011Date of Patent: June 11, 2013Assignee: AngioDevice International GmbHInventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline A. Schroeder, David M. Gravett, Philip M. Toleikis
-
Patent number: 8377466Abstract: A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.Type: GrantFiled: October 22, 2004Date of Patent: February 19, 2013Assignee: Angiotech Pharmaceuticals (US), Inc.Inventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Publication number: 20130012683Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: ANGIOTECH PHARMACEUTICALS (US), INC.Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis
-
Patent number: 8303973Abstract: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.Type: GrantFiled: September 19, 2005Date of Patent: November 6, 2012Assignee: Angiotech Pharmaceuticals (US), Inc.Inventors: George Y. Daniloff, Michael Huy Ngo, Olof Mikael Trollsas, David M. Gravett, Philip M. Toleikis